论文部分内容阅读
目的分析孕产妇围产期应用速碧林对深静脉血栓发生率的影响。方法选取2016年4月—2017年4月接受分娩手术的产妇162例,按照随机分配原则均分为对照组和研究组,各81例。两组产后均给予常规抗血栓治疗,研究组在此基础上给予速碧林治疗。观察两组产妇分娩后新生儿体重和胎盘平均重量,产妇机体凝血功能状况以及用药后不良反应发生情况。计量资料比较采用t检验,计数资料比较采用χ~2检验,P<0.05为差异有统计学意义。结果研究组新生儿胎龄、体重、及胎盘重量[(38.04±3.87)w、(3.76±0.84)kg、(436.91±61.52)g]高于对照组[(36.86±3.73)w、(2.48±0.77)kg、(345.6±55.42)g](均P<0.05),研究组新生儿窒息发生率(1.23%)低于对照组(11.11%);研究组治疗后Fbg和D-二聚体含量[(4.1±1.9)mg/L、(2.3±0.8)g/L]与对照组[(5.2±4.1)mg/L、(1.9±0.8)g/L]比较,差异有统计学意义(均P<0.05);研究组治疗后不良反应发生率低于对照组(P<0.05)。结论速碧林应用在孕产妇围术期可有效降低深静脉血栓发生率,取得理想的抗血栓效果。
Objective To analyze the effect of speedupin on the incidence of deep vein thrombosis during perinatal period in pregnant women. Methods Totally 162 maternal women undergoing childbirth from April 2016 to April 2017 were divided into control group and study group according to the principle of random distribution, each of 81 cases. Both groups were given conventional anti-thrombosis postpartum treatment, the study group on this basis to give speed Bilin treatment. Observe the weight of the newborn and the average weight of the placenta after maternal delivery in the two groups, the coagulation status of the maternal body and the adverse reactions after administration. Measurement data were compared using t test, count data were compared using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results The gestational age, body weight and placental weight in the study group [(38.04 ± 3.87) w, (3.76 ± 0.84) kg and (436.91 ± 61.52) g] were significantly higher than those in the control group [(36.86 ± 3.73) w and (P <0.05). The incidence of neonatal asphyxia in the study group (1.23%) was lower than that in the control group (11.11%). The levels of Fbg and D-dimer (4.1 ± 1.9) mg / L, (2.3 ± 0.8) g / L] compared with control group [(5.2 ± 4.1) mg / L and (1.9 ± 0.8) g / L], respectively P <0.05). The incidence of adverse reactions in the study group was lower than that in the control group (P <0.05). Conclusion Supibilin applied in maternal perioperative period can effectively reduce the incidence of deep venous thrombosis and achieve the desired anti-thrombotic effect.